| scholarly article | Q13442814 |
| P50 | author | Richard H Myers | Q42418674 |
| Peter Wilson | Q89854449 | ||
| P2093 | author name string | Schaefer EJ | |
| Salem DN | |||
| Ordovas JM | |||
| Genest JJ Jr | |||
| Jenner J | |||
| Martin-Munley SS | |||
| McNamara JR | |||
| Silberman SR | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lipoprotein | Q28350 |
| P304 | page(s) | 2025-2033 | |
| P577 | publication date | 1992-06-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Familial lipoprotein disorders in patients with premature coronary artery disease | |
| P478 | volume | 85 |
| Q41316306 | "Isolated" low high-density lipoprotein cholesterol |
| Q41495179 | A brief review paper of the efficacy and safety of atorvastatin in early clinical trials |
| Q44064895 | A candidate gene study in low HDL-cholesterol families provides evidence for the involvement of the APOA2 gene and the APOA1C3A4 gene cluster |
| Q73229430 | A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin |
| Q41996394 | A glimpse at HDL-based therapy for atherosclerosis |
| Q57840099 | A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis |
| Q44205520 | A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families |
| Q34335556 | A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity |
| Q24306084 | A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease |
| Q74561836 | A study of insulin resistance using the minimal model in nondiabetic familial combined hyperlipidemic patients |
| Q28219731 | ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease |
| Q24315861 | Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice |
| Q37104870 | Advances in the management of hyperlipidemia-induced atherosclerosis |
| Q44024429 | Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment |
| Q28586080 | Angptl3 regulates lipid metabolism in mice |
| Q46861175 | Antidiabetic potential of oleanolic acid from Ligustrum lucidum Ait. |
| Q85368754 | Apo A5 -1131T/C, FgB -455G/A, -148C/T, and CETP TaqIB gene polymorphisms and coronary artery disease in the Chinese population: a meta-analysis of 15,055 subjects |
| Q43546731 | Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study |
| Q36082750 | Association of rs5888 SNP in the scavenger receptor class B type 1 gene and serum lipid levels |
| Q85937411 | Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study) |
| Q41588632 | Candidate genes, small effects, and the prediction of atherosclerosis |
| Q21261519 | Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis |
| Q33582266 | Cardiovascular consequences of obese and nonobese obstructive sleep apnea |
| Q44352895 | Cardiovascular risk factors and testing of relatives amongst patients with familial hyperlipidaemia one decade after a clinical trial |
| Q43955486 | Carotid artery intima-media thickness in Finnish families with familial combined hyperlipidemia. |
| Q77299202 | Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment |
| Q90401914 | Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7 |
| Q36730810 | Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis |
| Q45246668 | Circulating C5L2 gene polymorphism is associated with type 2 diabetes mellitus in Saudi population |
| Q37835397 | Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein-deficiency states. |
| Q34990615 | Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity |
| Q35209308 | Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter |
| Q40440943 | Clustering of cardiovascular risk factors: Targeting high-risk individuals |
| Q33731864 | Combined hyperlipidemia as a risk factor for premature atherosclerotic disease |
| Q35919270 | Common variation in genes involved in HDL metabolism influences coronary heart disease risk at the population level |
| Q43796131 | Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease |
| Q39068223 | Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants |
| Q74693180 | Contribution of major cardiovascular risk factors to familial premature coronary artery disease: the GENECARD project |
| Q93135581 | Coronary Artery Disease Risk and Lipidomic Profiles Are Similar in Hyperlipidemias With Family History and Population-Ascertained Hyperlipidemias |
| Q36647940 | Coronary Heart Disease and Emotional Intelligence |
| Q36917287 | Coronary risk factors and metabolic disorders in first-degree relatives of normocholesterolaemic patients with premature atherosclerosis |
| Q42164926 | Correlation between the extent of coronary atherosclerosis and lipid profile |
| Q55475236 | DNA methylation in human lipid metabolism and related diseases. |
| Q74348218 | Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations |
| Q44460212 | Determinants of low HDL levels in familial combined hyperlipidemia |
| Q35917143 | Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study |
| Q34755683 | Diagnosis and management of lipoprotein abnormalities |
| Q28067479 | Diagnosis and treatment of high density lipoprotein deficiency |
| Q46114213 | Did grandma give you heart disease? The new battle against coronary artery disease |
| Q58147536 | Disorders of high‐density lipoprotein biogenesis |
| Q57730944 | Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism |
| Q34198872 | Effect of HDL composition and particle size on the resistance of HDL to the oxidation |
| Q41731952 | Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. |
| Q33600891 | Effects of Eicosapentaenoic Acid Supplementation on Lipid and Lipoprotein Profile in Hypertriglyceridemic Subjects with Different Proliferator-activated Receptor Alpha Genotypes |
| Q73009142 | Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels |
| Q73597780 | Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels |
| Q55710149 | Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid. |
| Q34808379 | Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism |
| Q43546756 | Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo A-I(Zaragoza) (L144R). |
| Q34491319 | Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease |
| Q33887894 | Epidemiology and prevention of coronary heart disease in families |
| Q24608464 | Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline |
| Q44625678 | Evidence of linkage of HDL level variation to APOC3 in two samples with different ascertainment |
| Q34390571 | Evidence of linkage of familial hypoalphalipoproteinemia to a novel locus on chromosome 11q23. |
| Q43687653 | Excess coronary heart disease in Familial Combined Hyperlipidemia, in relation to genetic factors and central obesity |
| Q38723704 | Experimental Biology for the Identification of Causal Pathways in Atherosclerosis |
| Q33619852 | Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway |
| Q44195486 | Familial combined hyperlipidemia plasma stimulates protein secretion by HepG2 cells: identification of fibronectin in the differential secretion proteome |
| Q72992412 | Familial hypercholesterolemia. Acceptor splice site (G-->C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G-->C] |
| Q40802354 | Familial lipoprotein disorders and premature coronary artery disease. |
| Q95816731 | Family coronary heart disease: a call to action |
| Q46227303 | Family history: a comprehensive genetic risk assessment method for the chronic conditions of adulthood |
| Q36623897 | Females with angina pectoris have altered lipoprotein metabolism with elevated cholesteryl ester transfer protein activity and impaired high-density lipoproteins-associated antioxidant enzymes |
| Q28284661 | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| Q53915752 | Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. |
| Q40436410 | Genetic Determinants of Myocardial Infarction |
| Q58545602 | Genetic and secondary causes of severe HDL deficiency and cardiovascular disease |
| Q35108611 | Genetic architecture of circulating lipid levels |
| Q35179025 | Genetic evaluation for coronary artery disease |
| Q36089523 | Genetic lipoprotein disorders and coronary atherosclerosis |
| Q47739423 | Genetic variation in the amino-terminal part of apolipoprotein B: studies in hyperlipidemic patients |
| Q36455894 | Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease |
| Q34107190 | Genetics of familial combined hyperlipidemia |
| Q77452737 | Genetics of lipoprotein disorders |
| Q37167765 | Genetics of premature myocardial infarction |
| Q34329091 | Genome scan for loci regulating HDL cholesterol levels in Finnish extended pedigrees with early coronary heart disease |
| Q35764851 | Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families |
| Q34389639 | Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels |
| Q64887324 | Glucose-6-Phosphate Dehydrogenase Deficiency is Associated with Cardiovascular Disease in U.S. Military Centers. |
| Q43219104 | Growth differentiation factor 15 and coronary collateral formation |
| Q34554267 | HDL and arteriosclerosis: beyond reverse cholesterol transport |
| Q37608502 | HDL inflammation and atherosclerosis: current and future perspectives |
| Q35754375 | HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease. |
| Q38087383 | HDL-C: clinical equipoise and vascular endothelial function |
| Q35266380 | Hereditary dyslipidemias and combined risk factors in children with a family history of premature coronary artery disease |
| Q37104643 | High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study |
| Q64286955 | High-density lipoprotein ameliorates palmitic acid-induced lipotoxicity and oxidative dysfunction in H9c2 cardiomyoblast cells via ROS suppression |
| Q51164566 | High-density lipoprotein subfractions and influence of endothelial lipase in a healthy Turkish population: a study in a land of low high-density lipoprotein cholesterol. |
| Q37718866 | High-density lipoproteins, platelets and the pathogenesis of atherosclerosis |
| Q35777408 | High-density lipoproteins: multifunctional vanguards of the cardiovascular system |
| Q46493757 | Hypertriglyceridemia is associated with prebeta-HDL concentrations in subjects with familial low HDL. |
| Q33652012 | Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease |
| Q43548774 | Identification of a common variant in the lipoprotein lipase gene in a large Utah kindred ascertained for coronary heart disease: the -93G/D9N variant predisposes to low HDL-C/high triglycerides |
| Q60302296 | Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials |
| Q54053962 | Impaired HDL response to fat in men with coronary artery disease. |
| Q37298694 | Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. |
| Q73943146 | Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease |
| Q48634633 | Interaction of family history of atherosclerosis with atherogenic lipid traits in men with non-coronary atherosclerosis |
| Q24642868 | Investigation of variants identified in caucasian genome-wide association studies for plasma high-density lipoprotein cholesterol and triglycerides levels in Mexican dyslipidemic study samples |
| Q34470216 | Is there a genetic basis for resistance to atherosclerosis? |
| Q47242605 | LDL Receptor Gene-ablated Hamsters: A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis |
| Q28267263 | Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23 |
| Q50954943 | Lipid abnormalities in Greek patients with coronary artery disease. |
| Q43813854 | Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study |
| Q35188357 | Lipoprotein disorders and cardiovascular risk |
| Q62273619 | Lipoprotein(A) in renal transplant recipients |
| Q43762325 | Lipoprotein(a) as a risk factor for maternal cardiovascular disease mortality in kindreds with familial combined hyperlipidemia or familial hypertriglyceridemia |
| Q77631965 | Lipoprotein(a) deposition is associated with the development of transplant renal arteriosclerosis in humans |
| Q77714432 | Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study |
| Q36232356 | Lipoprotein(a): implications for clinical practice |
| Q42631637 | Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia |
| Q77933878 | Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders |
| Q44471147 | Low HDL cholesterol concentration is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterol |
| Q35692886 | Management of dyslipidemias in the age of statins |
| Q40679542 | Management of older adults with hypercholesterolaemia |
| Q53621412 | Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL. |
| Q73857185 | Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (RE |
| Q41212011 | Molecular genetics as the route to understanding, prevention, and treatment |
| Q36742194 | Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium |
| Q28363810 | Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism |
| Q46630372 | Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia |
| Q22010457 | Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency |
| Q42924023 | Mutations in APOA-I and ABCA1 in Norwegians with low levels of HDL cholesterol |
| Q57241088 | Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux |
| Q37184990 | Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients |
| Q38227386 | NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links |
| Q61805056 | Natural Killer Response and Lipo-Metabolic Profile in Adults with Low HDL-Cholesterol and Mild Hypercholesterolemia: Beneficial Effects of Artichoke Leaf Extract Supplementation |
| Q38018722 | New directions in cardiovascular risk assessment: the role of secondary risk stratification markers |
| Q35052188 | New paradigms in preventive cardiology: unconventional coronary risk factors |
| Q38126418 | New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? |
| Q88682699 | Non-HDL-C levels and residual cardiovascular risk: Do population-specific precision approaches offer any advantages? |
| Q92619493 | Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes |
| Q24650988 | OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism |
| Q37267113 | Parity and serum lipid levels: a cross-sectional study in chinese female adults |
| Q36162860 | Patients with Rheumatoid Arthritis Show Altered Lipoprotein Profiles with Dysfunctional High-Density Lipoproteins that Can Exacerbate Inflammatory and Atherogenic Process |
| Q38055075 | Personalised nutrition: how far has nutrigenomics progressed? |
| Q36559160 | Personalized genomic medicine: a future prerequisite for the prevention of coronary artery disease. |
| Q73701461 | Phenotype expression in familial combined hyperlipidemia |
| Q37367246 | Plasma lipoproteins: genetic influences and clinical implications |
| Q45006115 | Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial |
| Q24610533 | Positional cloning of the combined hyperlipidemia gene Hyplip1 |
| Q41613122 | Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes |
| Q90435607 | Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease |
| Q46249438 | Prevalence of emerging cardiovascular risk factors in younger individuals with a family history of premature coronary heart disease and low Framingham risk score. |
| Q46684197 | Prevalence of obesity and its association with cardiovascular disease risk factors in adolescent girls from a college in central Taiwan |
| Q34003407 | Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment |
| Q41544724 | Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors |
| Q77714696 | Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention |
| Q36901653 | Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis |
| Q38839105 | Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. |
| Q34418506 | Psoriasis and comorbidities: links and risks |
| Q51865113 | Quantitative assessment of the effect of ABCA1 R219K polymorphism on the risk of coronary heart disease. |
| Q53938520 | Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. |
| Q43889907 | Recognition of familial dyslipidemias in 5-year-old children using the lipid phenotypes of parents. The STRIP project |
| Q73409229 | Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL families |
| Q33940989 | Relationship between a novel polymorphism of the C5L2 gene and coronary artery disease |
| Q36968971 | Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges |
| Q89272208 | Response of vascular mesenchymal stem/progenitor cells to hyperlipidemia |
| Q73691630 | Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia |
| Q34572932 | Screening relatives of patients with premature coronary heart disease |
| Q36763289 | Segregation analysis for high density lipoprotein in the Berkeley data. |
| Q50961761 | Serum complement and familial combined hyperlipidemia. |
| Q34574237 | Serum lipids in the GENECARD study of coronary artery disease identify quantitative trait loci and phenotypic subsets on chromosomes 3q and 5q. |
| Q41485239 | Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis |
| Q34107171 | Small, dense low-density lipoprotein subclass pattern B: issues for the clinician |
| Q73141379 | Soluble receptors for tumor necrosis factor-alpha (TNF-R p55 and TNF-R p75) in familial combined hyperlipidemia |
| Q46221019 | Srb1 maps to mouse chromosome 5 in a region harboring putative QTLs for plasma lipoprotein levels |
| Q54161119 | Studies in hypertriglyceridaemia, III: Glucose tolerance, insulin sensitivity and indices of adipose tissue lipolysis in randomly selected non-diabetic hypertriglyceridaemic Swedish men. |
| Q56982669 | Support for linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families |
| Q36030162 | The Contribution of GWAS Loci in Familial Dyslipidemias |
| Q52595882 | The Design and Rationale of SAVE BC: The Study to Avoid Vascular Events in British Columbia. |
| Q37375879 | The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia |
| Q91928918 | The abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects |
| Q38056160 | The association between psoriasis and dyslipidaemia: a systematic review |
| Q51565747 | The atherogenic significance of an elevated plasma triglyceride level. |
| Q41465052 | The genetic basis of atherosclerosis |
| Q34154477 | The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate |
| Q35017376 | The physiology of lipoproteins |
| Q39668034 | The relationship among brain natriuretic peptide (BNP), cholesterol and lipoprotein |
| Q45993645 | The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. |
| Q40921405 | The role of exercise training on lipoprotein profiles in adolescent males. |
| Q77309913 | The role of lipid-lowering therapy in multiple risk factor management |
| Q71802733 | The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis |
| Q37576100 | The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease |
| Q43478836 | The unresolved mystery of high-density lipoprotein: time for a paradigm shift? |
| Q73574896 | Treating isolated low high-density lipoprotein cholesterol: prescient or premature? |
| Q74646547 | Treatment of early onset atherosclerosis |
| Q33639909 | Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis |
| Q92649743 | Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk |
| Q44233907 | Triglycerides and atherogenic lipoproteins: rationale for lipid management |
| Q37244736 | Triglycerides and risk for coronary artery disease |
| Q46549705 | Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides |
| Q33594216 | Upstream transcription factor 1 influences plasma lipid and metabolic traits in mice |
| Q48033046 | Use of apolipoprotein parameters and endpoints in drug development and approval processes |
| Q36808835 | WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels |
| Q51574934 | [Goals and practical implementation of lipid therapy in coronary heart disease]. |
| Q53614132 | [Lipoprotein(a): influence on cardiovascular manifestation]. |
| Q74141140 | [Prevalence of dyslipidemia and its phenotypes in recently diagnosed essential arterial hypertension] |
Search more.